|
29.11.2016 14:45:01
|
DGAP-News: SYGNIS AG
DGAP-News: SYGNIS AG announces publication in 'Nature Communications' of the TruePrime(TM) novel method for whole genome amplification
- TruePrime(TM) promises to facilitate and improve single cell genomic analysis
- TruePrime(TM) is based on PrimPol, one of the most innovative discoveries in molecular biology
- Nature Communications is a worldwide reference publication for researchers
Madrid, Spain, and Heidelberg, Germany, November 29, 2016 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced publication of a technical paper on TruePrime(TM) in Nature Communications, an open access journal that publishes high-quality research in biology, physics, chemistry, Earth sciences, and all related areas. The article, titled: "TruePrime(TM) is a novel method for whole genome amplification from single cells based on TthPrimPol" is now available online at: http:// www.nature.com/articles/ncomms13296
The article discusses the novel TruePrime(TM) method, which facilitates and improves on single cell analysis by reducing bias and errors with other clear advantages when compared to current Gold standard DNA isothermal amplification methods.
Nature Communications is one of the most important references for researchers. As part of the publication process, the article is peer reviewed by world renowned opinion leaders. This review process validates SYGNIS' science and technology and enables the publication to have a significant impact in the scientific community, and can become an efficient marketing tool to promote new technologies.
Dr. Heikki Lanckriet, Co-CEO and CSO of SYGNIS, said: "Publication in Nature Communications is another key milestone achievement for us that will help to promote and validate our new technology, TruePrime(TM). TruePrime(TM) is one of the most innovative discoveries in the molecular biology field and one of the key products in SYGNIS' portfolio. This is proof of a growing awareness and interest in the scientific community for the importance of the combination of TthPrimPol's unique ability to synthesize DNA-primers with the highly processive Phi29 DNA polymerase to enable near complete whole genome amplification from single cells. The research and discovery SYGNIS undertook with Professor Luis Blanco's laboratory at Centro de Biología Molecular Severo Ochoa (CSIC-UAM) in Madrid, to discover PrimPol and afterwards to develop TruePrime(TM) is truly a paradigm shift for DNA or RNA amplification. We are very optimistic about the response that the scientific community will have after the publication of this article. As a result, we expect to have an important increase in the demand of TruePrime(TM) products. This article is part of our marketing strategy to promote and validate our most important technologies through leading worldwide scientific journals."
In July this year SYGNIS launched the TruePrime(TM) Single Cell WGA Kit V2 with significantly improved conditions for an expanded range of cell types and applications.
Abstract published in Nature Communications: "Sequencing of a single cell genome requires DNA amplification, a process prone to introducing bias and errors into the amplified genome. Here we introduce a novel multiple
displacement amplification (MDA) method based in the unique DNA primase features of Thermus thermophilus (Tth) PrimPol. TthPrimPol displays a potent primase activity preferring dNTPs as substrates unlike conventional primases. A combination of TthPrimPol's unique ability to synthesize DNA- primers with the highly processive Phi29 DNA polymerase (F29DNApol) enables near complete whole genome amplification from single cells. This novel method demonstrates superior breadth and evenness of genome coverage, high reproducibility, excellent single nucleotide variant (SNV) detection rates with low allelic dropout (ADO) and low chimera formation as exemplified by sequencing Hek293 cells. Moreover, copy number variant (CNV) calling yields superior results compared to random primer-based MDA methods. The advantages of this method, that we named TruePrime(TM), promise to facilitate and improve single cell genomic analysis."
For further information, please contact:
SYGNIS AG MC Services AG Pilar de la Huerta Raimund Gabriel Co-CEO/CFO Managing Partner Phone: +34 91 192 36 50 Phone: +49 89 210228 0 Email: pdelahuerta@sygnis.com Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS' product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).
### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward- looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###
---------------------------------------------------------------------------
29.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English Company: SYGNIS AG Waldhofer Str. 104 69123 Heidelberg Germany Phone: +49 (0) 6221 3540 125 Fax: +49 (0) 6221 3540 127 E-mail: investors@sygnis.com Internet: www.sygnis.com ISIN: DE000A1RFM03 WKN: A1RFM0 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service ---------------------------------------------------------------------------
525137 29.11.2016
DGAP-News: SYGNIS AG / Key word(s): Scientific publication
SYGNIS AG announces publication in 'Nature Communications' of the
TruePrime(TM) novel method for whole genome amplification
29.11.2016 / 14:45
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Press Release
SYGNIS AG announces publication in "Nature Communications" of the
TruePrime(TM) novel method for whole genome amplification
- TruePrime(TM) promises to facilitate and improve single cell genomic analysis
- TruePrime(TM) is based on PrimPol, one of the most innovative discoveries in molecular biology
- Nature Communications is a worldwide reference publication for researchers
Madrid, Spain, and Heidelberg, Germany, November 29, 2016 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced publication of a technical paper on TruePrime(TM) in Nature Communications, an open access journal that publishes high-quality research in biology, physics, chemistry, Earth sciences, and all related areas. The article, titled: "TruePrime(TM) is a novel method for whole genome amplification from single cells based on TthPrimPol" is now available online at: http:// www.nature.com/articles/ncomms13296
The article discusses the novel TruePrime(TM) method, which facilitates and improves on single cell analysis by reducing bias and errors with other clear advantages when compared to current Gold standard DNA isothermal amplification methods.
Nature Communications is one of the most important references for researchers. As part of the publication process, the article is peer reviewed by world renowned opinion leaders. This review process validates SYGNIS' science and technology and enables the publication to have a significant impact in the scientific community, and can become an efficient marketing tool to promote new technologies.
Dr. Heikki Lanckriet, Co-CEO and CSO of SYGNIS, said: "Publication in Nature Communications is another key milestone achievement for us that will help to promote and validate our new technology, TruePrime(TM). TruePrime(TM) is one of the most innovative discoveries in the molecular biology field and one of the key products in SYGNIS' portfolio. This is proof of a growing awareness and interest in the scientific community for the importance of the combination of TthPrimPol's unique ability to synthesize DNA-primers with the highly processive Phi29 DNA polymerase to enable near complete whole genome amplification from single cells. The research and discovery SYGNIS undertook with Professor Luis Blanco's laboratory at Centro de Biología Molecular Severo Ochoa (CSIC-UAM) in Madrid, to discover PrimPol and afterwards to develop TruePrime(TM) is truly a paradigm shift for DNA or RNA amplification. We are very optimistic about the response that the scientific community will have after the publication of this article. As a result, we expect to have an important increase in the demand of TruePrime(TM) products. This article is part of our marketing strategy to promote and validate our most important technologies through leading worldwide scientific journals."
In July this year SYGNIS launched the TruePrime(TM) Single Cell WGA Kit V2 with significantly improved conditions for an expanded range of cell types and applications.
Abstract published in Nature Communications: "Sequencing of a single cell genome requires DNA amplification, a process prone to introducing bias and errors into the amplified genome. Here we introduce a novel multiple
displacement amplification (MDA) method based in the unique DNA primase features of Thermus thermophilus (Tth) PrimPol. TthPrimPol displays a potent primase activity preferring dNTPs as substrates unlike conventional primases. A combination of TthPrimPol's unique ability to synthesize DNA- primers with the highly processive Phi29 DNA polymerase (F29DNApol) enables near complete whole genome amplification from single cells. This novel method demonstrates superior breadth and evenness of genome coverage, high reproducibility, excellent single nucleotide variant (SNV) detection rates with low allelic dropout (ADO) and low chimera formation as exemplified by sequencing Hek293 cells. Moreover, copy number variant (CNV) calling yields superior results compared to random primer-based MDA methods. The advantages of this method, that we named TruePrime(TM), promise to facilitate and improve single cell genomic analysis."
For further information, please contact:
SYGNIS AG MC Services AG Pilar de la Huerta Raimund Gabriel Co-CEO/CFO Managing Partner Phone: +34 91 192 36 50 Phone: +49 89 210228 0 Email: pdelahuerta@sygnis.com Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS' product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).
### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward- looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###
---------------------------------------------------------------------------
29.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English Company: SYGNIS AG Waldhofer Str. 104 69123 Heidelberg Germany Phone: +49 (0) 6221 3540 125 Fax: +49 (0) 6221 3540 127 E-mail: investors@sygnis.com Internet: www.sygnis.com ISIN: DE000A1RFM03 WKN: A1RFM0 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service ---------------------------------------------------------------------------
525137 29.11.2016
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Expedeon (ex Sygnis)mehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Expedeon (ex Sygnis)mehr Analysen
Letzte Top-Ranking Nachrichten
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.